Company facts
- Headquarters
- Irvine, California
- Most recent report
- 10-Q, filed Aug 6, 2026
- Incorporated
- Delaware
- Filings on record
- 82 filings
- On EDGAR
- CIK 1778922
- Fiscal year ends
- December
- Filer status
- Non-accelerated filer Smaller reporting company Emerging growth company
Financials 3
News 6
Prospectuses and Registrations 4
Ownership 8 of 60
- SCHEDULE 13G Large holder reported a passive stake Feb 17, 2026
- SCHEDULE 13D Large holder reported an active stake Feb 17, 2026
- SCHEDULE 13D Large holder reported an active stake Feb 13, 2026
- SCHEDULE 13D Large holder reported an active stake Feb 13, 2026
- SCHEDULE 13G Large holder reported a passive stake Feb 13, 2026
- 4 Insider reported a trade Feb 11, 2026
- 4/A Insider reported a trade, amended Feb 11, 2026
- 4 Insider reported a trade Feb 11, 2026
Other 8 of 9
- CERT Exchange certified a listing Feb 5, 2026
- 8-A12B Registration of a security for exchange listing Feb 5, 2026
- EFFECT Notice that a registration became effective Jan 30, 2026
- DRS/A Draft registration statement, submitted confidentially, amended Dec 10, 2025
- DRS Draft registration statement, submitted confidentially Sep 26, 2025
- D Jun 5, 2025
- D Jul 11, 2023
- D Jan 5, 2021
Everything here comes from SpyGlass Pharma, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.